Invivyd’s (IVVD) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Invivyd (NASDAQ:IVVD) in a research report released on Monday morning,Benzinga reports. They currently have a $10.00 target price on the stock.

Several other analysts have also recently commented on the stock. EF Hutton Acquisition Co. I raised shares of Invivyd to a “strong-buy” rating in a research note on Wednesday, October 30th. D. Boral Capital reaffirmed a “buy” rating and issued a $9.00 target price on shares of Invivyd in a research note on Monday. Finally, Morgan Stanley lowered their target price on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research note on Wednesday, November 20th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Invivyd presently has an average rating of “Buy” and an average price target of $7.89.

Invivyd Price Performance

Shares of Invivyd stock opened at $1.23 on Monday. Invivyd has a 1 year low of $0.35 and a 1 year high of $4.74. The company has a market capitalization of $147.13 million, a P/E ratio of -0.63 and a beta of 0.61. The business has a 50 day moving average price of $0.84 and a 200 day moving average price of $0.87.

Insider Activity

In other news, Director Terrance Mcguire sold 65,359 shares of the business’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $0.47, for a total transaction of $30,718.73. Following the completion of the sale, the director now directly owns 4,012,320 shares of the company’s stock, valued at $1,885,790.40. The trade was a 1.60 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders sold 816,466 shares of company stock valued at $423,214 in the last ninety days. Company insiders own 17.90% of the company’s stock.

Institutional Trading of Invivyd

Several institutional investors have recently made changes to their positions in IVVD. Mithril II GP LP purchased a new stake in Invivyd during the 4th quarter worth $4,981,000. Two Sigma Advisers LP boosted its position in Invivyd by 1,276.5% during the 4th quarter. Two Sigma Advisers LP now owns 304,200 shares of the company’s stock worth $135,000 after purchasing an additional 282,100 shares during the period. Deutsche Bank AG boosted its position in Invivyd by 35.2% during the 4th quarter. Deutsche Bank AG now owns 874,406 shares of the company’s stock worth $385,000 after purchasing an additional 227,463 shares during the period. JPMorgan Chase & Co. boosted its position in Invivyd by 644.1% during the 4th quarter. JPMorgan Chase & Co. now owns 256,900 shares of the company’s stock worth $114,000 after purchasing an additional 222,375 shares during the period. Finally, Two Sigma Investments LP boosted its position in Invivyd by 125.3% during the 4th quarter. Two Sigma Investments LP now owns 367,100 shares of the company’s stock worth $163,000 after purchasing an additional 204,188 shares during the period. 70.36% of the stock is owned by hedge funds and other institutional investors.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.